Genpact LTD (G) SEC Filings, Sep-Nov 2025

Form 144 notice: A holder identified as Sameer Dewan filed to sell up to 26,531 shares of the issuer’s common stock through Morgan Stanley Smith Barney LLC Executive Financial Services. The filing lists an aggregate market value of $1,185,999.37 and an approximate sale date of 11/11/2025 on the NYSE.

The shares were acquired from the issuer via equity awards: performance shares and restricted stock granted on 01/10/2021, 01/10/2022, and 01/10/2023, matching the proposed sale amount. Shares outstanding were 172,414,423. Over the past three months, the seller reported a prior sale of 20,078 shares on 08/28/2025 for gross proceeds of $903,510.

Genpact Limited reported higher quarterly results. Net revenues for Q3 2025 rose to $1,291,257 from $1,210,949 a year ago, with income from operations of $191,642. Net income increased to $145,831, and diluted EPS was $0.83 versus $0.74.

For the first nine months of 2025, net revenues reached $3,760,601 and net income was $409,400, with diluted EPS of $2.31. Operating cash flow strengthened to $526,161, supporting buybacks and dividends. Cash and cash equivalents were $740,763 as of September 30, 2025.

The company completed the acquisition of XponentL Data, Inc. for total consideration of $160,157, including $82,657 in cash at closing and an earn-out of $77,500. The deal added customer-related intangibles of $51,400 and goodwill of $112,271. Genpact repurchased 3,919,239 shares year-to-date for $182,905 and paid dividends totaling $88,701. Long-term debt (less current) declined to $827,046, while the current portion rose to $375,871, reflecting near-term maturities.

Genpact Limited furnished an update under Item 2.02, announcing it issued a press release with financial results for the three months ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference.

The information, including Exhibit 99.1, is furnished—not filed—so it is not subject to Section 18 of the Exchange Act and will only be incorporated into other filings if expressly referenced. The company references non-GAAP measures in the release and provides reconciliations to comparable GAAP measures within Exhibit 99.1.

Genpact Ltd (G) reported an equity award to an officer. On 10/10/2025, the Chief Accounting Officer acquired 20,066 common shares at $0, reported as an award of unvested restricted share units under the Genpact Limited 2017 Omnibus Incentive Compensation Plan. Following the transaction, beneficial ownership was 20,066 shares, held directly.

Each RSU converts into one common share upon vesting. The award vests in three equal installments on April 30, 2027, July 31, 2027, and October 31, 2027, subject to continued service through each vesting date.

Genpact LTD (G) filing an initial Form 3 shows Anthony J. Radesca, the company's Chief Accounting Officer and an officer-level reporting person, reported no beneficial ownership of Genpact securities.

The form lists the event date as 09/29/2025 and the filing was signed on 10/06/2025 by an attorney-in-fact. The filing includes an exhibit referencing a power of attorney and confirms this is an individual filing by one reporting person.

Genpact disclosed the appointment of Mr. Radesca as Senior Vice President and Chief Accounting Officer. The filing states he will receive a base salary, annual bonus opportunities, and equity awards appropriate to his role, and will be eligible for Company-sponsored benefits such as health, disability, and life insurance. The company disclosed there are no arrangements or understandings with other persons regarding his appointment, no family relationships with any director or executive officer, and no transactions in the last fiscal year (and none proposed) that would trigger related‑party disclosure under Regulation S-K Item 404(a).

Insider transactions by Genpact Ltd (G): Senior Vice President and CHRO Piyush Mehta executed multiple transactions on 09/12/2025. He acquired 50,000 common shares at $31.50, and sold 50,000 shares and 26,902 shares at weighted-average prices of $42.58 (sales ranged from $42.42 to $42.73 and $42.42 to $42.70 respectively). After these transactions he beneficially owns 134,880 common shares. The filing notes he holds 10,222 shares under the ESPP (including 284 shares acquired since his prior Form 4). The Form 4 was signed by an attorney-in-fact on 09/15/2025.

Insider transactions by Genpact Ltd director and CEO Balkrishan Kalra. On 09/11/2025 Mr. Kalra sold 15,000 common shares at a weighted-average price of approximately $43.39 and sold 40,000 common shares at a weighted-average price of approximately $43.35, reducing his reported beneficial ownership to 295,246 shares. On the same date he acquired 40,000 common shares by exercising employee stock options at a $27.65 exercise price, bringing his beneficial ownership to 335,246 shares before the net sales shown. The Form 4 shows the option originally vested in two tranches (50% on 01/10/2019 and the remainder on 01/10/2021) and lists 40,000 underlying shares exercised with 2,800 derivative securities remaining reported as beneficially owned. Transactions were signed by an attorney-in-fact on 09/15/2025.

Genpact Limited reported that its Chief Accounting Officer and principal accounting officer, Donald Klunk, will separate from the company effective September 18, 2025, following a mutual agreement reached on September 11, 2025. The company states that his departure is not due to any disagreements with management or auditors regarding accounting principles, financial statement disclosures, or internal controls. Following his departure, Chief Financial Officer Michael Weiner will serve as the interim principal accounting officer until a successor is announced. Genpact also notes its appreciation for Mr. Klunk’s contributions and years of service.